A5019624513- Sarcoma Diagnosis and Treatment
- Gastrointestinal Tumor Research and Treatment
- Vascular Tumors and Angiosarcomas
- Gastric Cancer Management and Outcomes
- Cardiac tumors and thrombi
- Ovarian cancer diagnosis and treatment
- Gastrointestinal disorders and treatments
- Cancer Genomics and Diagnostics
- Neurofibromatosis and Schwannoma Cases
- Childhood Cancer Survivors' Quality of Life
- Uterine Myomas and Treatments
- Bone Tumor Diagnosis and Treatments
- Lymphoma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Endometrial and Cervical Cancer Treatments
- Soft tissue tumors and treatment
- Health Systems, Economic Evaluations, Quality of Life
- Cancer survivorship and care
- Colorectal and Anal Carcinomas
- CAR-T cell therapy research
- Soft tissue tumor case studies
- Medication Adherence and Compliance
- Oral and Maxillofacial Pathology
- Cancer Treatment and Pharmacology
- Renal cell carcinoma treatment
Centre Léon Bérard
2009-2024
Université Claude Bernard Lyon 1
2015-2024
Centre de Recherche en Cancérologie de Lyon
2024
Institut Bergonié
2009-2024
Inserm
2024
Institut Curie
2024
Institut Gustave Roussy
2024
Université de Bordeaux
2024
Institute Cancer De La Loire Lucien Neuwirth
2014-2023
Centre Hospitalier Universitaire de Nantes
2020
NETSARC (netsarc.org) is a network of 26 sarcoma reference centers with specialized multidisciplinary tumor boards (MDTB) aiming to improve the outcome patients. Since 2010, presentation an MDTB and expert pathological review are mandatory for patients nationwide. In present work, impact surgery in center on survival investigated using this national registry.
The addition of trabectedin to doxorubicin, followed by maintenance, may have superior efficacy doxorubicin alone as first-line treatment in patients with advanced leiomyosarcoma.
Abstract Background. Angiosarcomas account for <2% of all soft tissue sarcomas. This subtype is one the most aggressive forms sarcoma. The prognosis angiosarcoma patients in advanced phase remains poor with current cytotoxic agents (progression-free survival [PFS] time ∼4 months and overall [OS] ∼8 months). We investigated antitumor activity sorafenib metastatic or angiosarcomas a II trial. Methods. conducted stratified primary endpoint was progression-free rate (PFR) at 9 according...
Purpose The aim of this randomized, phase II trial was to explore the activity and safety adding bevacizumab paclitaxel once per week in treatment angiosarcomas (AS). Methods Patients were treated with alone (90 mg/m2 for six cycles 28 days each; arm A) or combined (10 mg/kg every 2 weeks; B). In combination arm, administered after chemotherapy as maintenance therapy (15 3 weeks) until intolerance progression occurred. Stratification factors superficial versus visceral AS de novo...
There is no consensual treatment of locally advanced or metastatic chordomas.We conducted a multicenter, open-label, uncontrolled phase II trial sorafenib (800 mg/day). The primary end point was the 9-month progression-free rate according to RECIST 1.1. All patients had documented progressive disease at time study entry.Twenty-seven were enrolled between May 2011 and January 2014. median age 64 (range, 30-86) years. 17 men 10 women. Twelve been previously treated with chemotherapy...
The outcome of sarcoma has been suggested in retrospective and non-exhaustive studies to be better through management by a multidisciplinary team experts adherence clinical practice guidelines (CPGs). aim this prospective exhaustive population based study was confirm the impact CPGs on survival patients with localized sarcoma.Between 2005 2007, all evaluable adult newly diagnosis located Rhone Alpes region (n = 634), including 472 cases soft-tissue (STS), were enrolled. prognostic...
The long term outcome of advanced sarcoma patients treated with trabectedin outside clinical trials and the utility maintenance treatment has not been reported. Between 2003 2008, failing doxorubicin could be within a compassionate use program (ATU, Temporary Use Authorization) in France using standard 3-weekly regimen. Data from 181 (55%) were collected 11 centres analyzed. Trabectedin was given first, second, third or fourth line metastatic phase 6%, 37%, 33% 23% respectively. With median...
Although cemiplimab has been approved for locally advanced (la) and metastatic (m) cutaneous squamous-cell carcinomas (CSCCs), its real-life value not yet demonstrated. An early-access program enrolled patients with la/mCSCCs to receive cemiplimab. Endpoints were best overall response rate (BOR), progression-free survival (PFS), (OS), duration of (DOR) safety. The 245 (mean age 77 years, 73% male, 49% prior systemic treatment, 24% immunocompromised, 27% Eastern Cooperative Oncology Group...
In the OS2006 study, patients younger than 18 years were treated with a methotrexate‐based regimen (MTX), older 25 doxorubicin–cisplatin–ifosfamide‐based (API–AI), whereas aged 18–25 received either API–AI or MTX. We herein report prespecified subgroup analysis of outcome 106 API–AI. Preoperative chemotherapy combined three doxorubicin–ifosfamide–cisplatin (API) and two doxorubicin–ifosfamide (AI) courses. Postoperative was assigned by risk group: localised good histological response...
Rectal and pararectal gastrointestinal stromal tumors (GISTs) are rare. The optimal management strategy for primary localized GISTs remains poorly defined. We conducted a retrospective analysis of 41 patients with rectal or treated between 1991 2011 in 13 French Sarcoma Group centers. Of 12 who received preoperative imatinib therapy median duration 7 (2-12) months, 8 experienced partial response, 3 had stable disease, 1 complete response. Thirty 11 underwent function-sparing conservative...